Thymosin alpha-1 side effects and risks

Reported side effects

• Injection-site discomfort or redness: Foreign information reports <1% drug related events overall in over 2,000 people; no site specific rate., mild. Report persistent pain, swelling or redness; worsening local changes can signal infection. (source)
• Rash, joint pain or hand swelling: Described as rare in foreign product information; exact counts were not supplied., moderate. Stop dosing and seek assessment if symptoms spread or persist. (source)
• Liver-test flares during hepatitis B dosing: 22/316 in the Japanese trial, 11 at each dose; arm specific percentages not extracted., moderate. Needs liver tests and clinical review; jaundice, confusion or bleeding need urgent care. (source)
• Serious immune reaction with checkpoint therapy: One 2026 case involved fever, rash and multiple organ injury after sintilimab plus TA1., serious. Urgent assessment for fever, rash, breathing trouble or jaundice during cancer immune therapy. (source)
• Events during intensive-care treatment: TESTS: any event 66.4% versus 67.6% placebo; serious events 26.8% versus 29.3%., serious. These are all-cause events in critically ill patients, not TA1-attributed side-effect rates. (source)
• Worse fatigue, sleep or swollen glands: Self reports include worsening after 100 mcg once; no incidence or causality can be calculated., moderate. Do not assume a worsening reaction means the product is working. Seek assessment. (source)

Stop and get help if

• Trouble breathing, throat or face swelling, widespread hives or fainting after an injection: Stop dosing and get emergency care for a possible severe allergic reaction.
• High fever, rapidly spreading rash, chest tightness or new breathing trouble during cancer immune therapy: Seek urgent hospital assessment; severe immune toxicity and infection can look alike.
• Jaundice, confusion, vomiting blood or new severe abdominal swelling: Get urgent care for possible liver failure or bleeding.
• Worsening injection-site redness, warmth, pus or fever: Get prompt assessment for injection-related infection.

Who should avoid it

• pregnant: Human pregnancy safety is unknown. Foreign product information does not establish fetal safety.
• breastfeeding: It is unknown whether TA1 enters human milk or affects a nursing infant.
• tryingToConceive: Reproductive safety in humans is not established; this is a precaution, not evidence of infertility.
• under18: Safety and effectiveness below 18 are not established in the inspected foreign product information.
• other: Foreign product information contraindicates use after hypersensitivity to TA1 or its ingredients.
• other: Foreign instructions contraindicate deliberate immune suppression unless a specialist judges benefits outweigh risks.
• immunosuppressed: Low immune function from HIV or cancer differs from deliberate immune suppression. Trials used specialist care and do not establish routine self-use.
• autoimmuneDisease: Effects in active autoimmune disease are uncertain. Major sepsis trials excluded acute autoimmune disease.
• liverDisease: Hepatitis B dosing can cause liver-test flares. Cirrhosis or liver failure needs disease-specific monitoring.
• kidneyDisease: A small dialysis trial does not establish a general kidney-dose adjustment or long-term safety rule.
• activeCancer: TA1 has been studied with cancer drugs, but a severe immune reaction was reported with checkpoint therapy. Coordinate with oncology.
• testedAthlete: TA1 is not named in the 2026 list. Obtain a compound-specific ruling; the named thymosin beta-4 ban concerns a different peptide.

Interactions

• Other immune-suppressing drugs: Review the reason for immune suppression and the intended TA1 effect. Formal interaction studies are incomplete.
• Transplant immune-suppressing medicines: TA1 may oppose transplant immune suppression. Foreign instructions flag deliberate immune suppression as a contraindication.
• Immune checkpoint inhibitors: Severe multi-organ immune toxicity was reported with sintilimab plus TA1. Risk across this drug class is unknown.
• Interferon products: Studied together, but adds the risks of interferon; thyroid-function changes occurred in an older combination study.
• Vaccines: TA1 has been studied as a vaccine add-on. Sustained benefit is uncertain, and combining it without review can alter immune response.
• Other thymic or immune peptides: Check for duplicate TA1 exposure. Combining immune peptides has no established safety or interaction map.

Product quality risks

• FDA flags peptide impurities, uncertain characterization and immune-reaction risk for compounded TA1.
• Unregulated injections can have the wrong amount, unknown ingredients, particles, microbes or endotoxin.
• A purity percentage does not establish the amount per vial, sterility, endotoxin level or clinical safety.